The company said consolidated revenue for Q2 2024 (3 months) rose 6.2% to $717 million, and Adjusted EBITDA rose 8.8% to $397 million. Adjusted EBITDA is a non-GAAP measure, and organic constant currency growth was 8.5%.

1. 01

   The company said consolidated revenue for Q2 2024 (3 months) rose 6.2% to $717 million, and Adjusted EBITDA rose 8.8% to $397 million. Adjusted EBITDA is a non-GAAP measure, and organic constant currency growth was 8.5%.

2. 02

   Verisk said income from continuing operations for Q2 rose 50.7% to $308 million. The company cited net gains of $98.3 million from the settlement of retained interests tied to its prior sales of the healthcare business in 2016 and the specialized markets business in 2022 as factors behind the increase.

3. 03

   The company said net cash provided by operating activities for Q2 2024 (3 months) rose 9.7% to $212 million, and free cash flow rose 14.3% to $154 million. Free cash flow is a non-GAAP measure.

4. 04

   Verisk said it began a $150 million Accelerated Share Repurchase program in Q2 and completed it in July. It said it had $1.3 billion remaining under its share repurchase authorization as of June 30, 2024. The company also paid a cash dividend of 39 cents per share on June 28.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.